Immunotherapy in Children: Report from the Reisensburg-Symposium October 20-22, 2004[*] and Recent Advances

Abstract

Immunotherapy of childhood malignancies has a magic aura of promising an easy way to cure. It is not only the public, but also the medical community, which has caused this hope. Therefore, it was worthwhile to bring together a panel of experts working in the field of immunotherapy in order to discuss ongoing projects, and to show hopes and disappointments. The result was a fascinating symposium sponsored by The Kind Philipp Leukemia Foundation (Mönchengladbach, Germany). The symposium took place in the Reissensburg near Ulm (Germany) which gives the ideal location for such an event.

Zusammenfassung

Diskussionen über Immuntherapie von Krebserkrankungen bei Kindern waren von jeher umgeben von einer Aura der magischen Versprechung eines sanften Wegs zur Heilung. Die damit verbundenen, durchaus unrealistischen Hoffnungen wurden oft nicht nur von einer interessierten Öffentlichkeit, sondern auch von den wissenschaftlich auf diesem Gebiet arbeitenden Medizinern selbst geschürt. Es war daher sinnvoll, Experten auf diesem Gebiet zusammenzubringen und mit ihnen ihre Projekte, die begründeten Hoffnungen, aber auch die erlebten Enttäuschungen kritisch zu diskutieren. Es entstand ein faszinierendes Symposium, das durch die Kind-Philipp-Leukämie-Stiftung (Mönchengladbach, Deutschland) ermöglicht und finanziert wurde und in der Reisensburg nahe Ulm (Deutschland) seinen idealen Veranstaltungsort fand.

immunotherapy - children - clinical application - phase I/II studies

Immuntherapie - Kinder - klinische Erfahrungen - Phase-I und II-Studien

References

• 1 Ackermann B, Troger A, Glouchkova L, Korholz D, Gobel U, Dilloo D. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.  Klin Padiatr. 2004;  216 176-182
• 2 Alvarez-Vallina L, Hawkins R E. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors.  Eur J Immunol. 1996;  26 2304-2309
• 3 Amrolia P J, Muccioli-Casadei G, Yvon E, Huls H, Sili U, Wieder E D, Bollard C, Michalek J, Ghetie V, Heslop H E, Molldrem J J, Rooney C M, Schlinder J, Vitetta E, Brenner M K. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.  Blood. 2003;  102 2292-2299
• 4 Amrolia P J, Rao K, Slater O, Ramsay A, Veys P A, Webb D K. Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion.  Bone Marrow Transplant. 2001;  28 623-625
• 5 Amrolia P J, Reid S D, Gao L, Schultheis B, Dotti G, Brenner M K, Melo J V, Goldman J M, Stauss H J. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.  Blood. 2003;  101 1007-1014
• 6 Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, Kremens B, Dilloo D, Sykora K W, Schrappe M, Niemeyer C, Stackelberg  von A, Gruhn B, Henze G, Greil J, Niethammer D, Dietz K, Beck J F, Klingebiel T. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?.  J Clin Oncol. 2004;  22 1696-1705
• 7 Bader P, Kreyenberg H, Hoelle W, Dueckers G, Kremens B, Dilloo D, Sykora K W, Niemeyer C, Reinhardt D, Vormoor J, Gruhn B, Lang P, Greil J, Handgretinger R, Niethammer D, Klingebiel T, Beck J F. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective.  Bone Marrow Transplant. 2004;  33 815-821
• 8 Bellocchio S, Bozza S, Montagnoli C, Perruccio K, Gaziano R, Pitzurra L, Romani L. Immunity to Aspergillus fumigatus: the basis for immunotherapy and vaccination.  Med Mycol. 2005;  43 (Suppl 1) S 181-S 188
• 9 Bellocchio S, Gaziano R, Bozza S, Rossi G, Montagnoli C, Perruccio K, Calvitti M, Pitzurra L, Romani L. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.  J Antimicrob Chemother. 2005;  55 214-222
• 10 Bellocchio S, Montagnoli C, Bozza S, Gaziano R, Rossi G, Mambula S S, Vecchi A, Mantovani A, Levitz S M, Romani L. The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo.  J Immunol. 2004;  172 3059-3069
• 11 Bellocchio S, Moretti S, Perruccio K, Fallarino F, Bozza S, Montagnoli C, Mosci P, Lipford G B, Pitzurra L, Romani L. TLRs govern neutrophil activity in aspergillosis.  J Immunol. 2004;  173 7406-7415
• 12 Bollard C M, Aguilar L, Straathof K C, Gahn B, Huls M H, Rousseau A, Sixbey J, Gresik M V, Carrum G, Hudson M, Dilloo D, Gee A, Brenner M K, Rooney C M, Heslop H E. Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's disease.  J Exp Med. 2004;  200 1623-1633
• 13 Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.  Science. 1997;  276 1719-1724
• 14 Cavalieri S, Cazzaniga S, Geuna M, Magnani Z, Bordignon C, Naldini L, Bonini C. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence.  Blood. 2003;  102 497-505
• 15 Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.  N Engl J Med. 2002;  346 235-242
• 16 Dagher R, Long L M, Read E J, Leitman S F, Carter C S, Tsokos M, Goletz T J, Avila N, Berzofsky J A, Helman L J, Mackall C L. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study.  Med Pediatr Oncol. 2002;  38 158-164
• 17 Felzmann T, Huttner K G, Breuer S K, Wimmer D, Ressmann G, Wagner D, Paul P, Lehner M, Heitger A, Holter W. Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses.  Cancer Immunol Immunother. 2005;  54 769-780
• 18 Finney H M, Akbar A N, Lawson A D. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.  J Immunol. 2004;  172 104-113
• 19 Geiger C, Regn S, Weinzierl A, Noessner E, Schendel D J. A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.  J Transl Med. 2005;  3 29
• 20 Geiger J D, Hutchinson R J, Hohenkirk L F, McKenna E A, Yanik G A, Levine J E, Chang A E, Braun T M, Mule J J. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.  Cancer Res. 2001;  61 8513-8519
• 21 Grau R, Lang K S, Wernet D, Lang P, Niethammer D, Pusch C M, Handgretinger R. Cytotoxic activity of natural killer cells lacking killer-inhibitory receptors for self-HLA class I molecules against autologous hematopoietic stem cells in healthy individuals.  Exp Mol Pathol. 2004;  76 90-98
• 22 Heslop H E, Savoldo B, Rooney C M. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease.  Best Pract Res Clin Haematol. 2004;  17 401-413
• 23 Junker K, Koehl U, Zimmerman S, Stein S, Schwabe D, Klingebiel T, Grez M. Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes.  Gene Ther. 2003;  10 1189-1197
• 24 Koehl U, Sorensen J, Esser R, Zimmermann S, Gruttner H P, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.  Blood Cells Mol Dis. 2004;  33 261-266
• 25 Krafft H, Cichutek K. [Approval of clinical trials of immunobiological medicinal products at the Paul Ehrlich Institute].  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005;  48 168-172
• 26 Lang P, Barbin K, Feuchtinger T, Greil J, Peipp M, Zunino S J, Pfeiffer M, Handgretinger R, Niethammer D, Fey G H. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts.  Blood. 2004;  103 3982-3985
• 27 Lang P, Pfeiffer M, Handgretinger R, Schumm M, Demirdelen B, Stanojevic S, Klingebiel T, Kohl U, Kuci S, Niethammer D. Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children.  Bone Marrow Transplant. 2002;  29 497-502
• 28 Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.  Lancet. 2004;  363 1439-1441
• 29 Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D, Handgretinger R. Determinants of antileukemia effects of allogeneic NK cells.  J Immunol. 2004;  172 644-650
• 30 Lode H N, Huebener N, Zeng Y, Fest S, Weixler S, Gaedicke G. DNA minigene vaccination for adjuvant neuroblastoma therapy.  Ann N Y Acad Sci. 2004;  1028 113-121
• 31 Lode H N, Pertl U, Xiang R, Gaedicke G, Reisfeld R A. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma.  Med Pediatr Oncol. 2000;  35 641-646
• 32 Lode H N, Xiang R, Duncan S R, Theofilopoulos A N, Gillies S D, Reisfeld R A. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.  Proc Natl Acad Sci USA. 1999;  96 8591-8596
• 33 Lode H N, Xiang R, Gillies S D, Reisfeld R A. Amplification of T cell-mediated immune responses by antibody-cytokine fusion proteins.  Immunol Invest. 2000;  29 117-120
• 34 Lode H N, Xiang R, Perri P, Pertl U, Lode A, Gillies S D, Reisfeld R A. What to do with targeted IL-2.  Drugs Today (Barc). 2000;  36 321-336
• 35 Lowe E J, Turner V, Handgretinger R, Horwitz E M, Benaim E, Hale G A, Woodard P, Leung W. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation.  Br J Haematol. 2003;  123 323-326
• 36 Mackall C L. Enhancing immune reconstitution after stem cell transplants with cytokines.  Cytotherapy. 2002;  4 427-428
• 37 Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.  Blood. 2004;  103 4619-4621
• 38 Moretta L, Moretta A. Killer immunoglobulin-like receptors.  Curr Opin Immunol. 2004;  16 626-633
• 39 Passweg J R, Stern M, Koehl U, Uharek L, Tichelli A. Use of natural killer cells in hematopoetic stem cell transplantation.  Bone Marrow Transplant. 2005;  35 637-643
• 40 Qasim W, Gaspar H B, Thrasher A J. T cell suicide gene therapy to aid haematopoietic stem cell transplantation.  Curr Gene Ther. 2005;  5 121-132
• 41 Robinet E, Fehse B, Ebeling S, Sauce D, Ferrand C, Tiberghien P. Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function.  Cytotherapy. 2005;  7 150-157
• 42 Rossig C, Brenner M K. Genetic modification of T lymphocytes for adoptive immunotherapy.  Mol Ther. 2004;  10 5-18
• 43 Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin R S, Martelli M F, Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.  Blood. 1999;  94 333-339
• 44 Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik W D, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli M F, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.  Science. 2002;  295 2097-2100
• 45 Ruggeri L, Mancusi A, Capanni M, Martelli M F, Velardi A. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer.  Curr Opin Immunol. 2005;  17 211-217
• 46 Schilbach K, Kerst G, Walter S, Eyrich M, Wernet D, Handgretinger R, Xie W, Rammensee H G, Muller I, Buhring H J, Niethammer D. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction.  Blood. 2005;  106 144-149
• 47 Schmidt S M, Schag K, Muller M R, Weinschenk T, Appel S, Schoor O, Weck M M, Grunebach F, Kanz L, Stevanovic S, Rammensee H G, Brossart P. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.  Cancer Res. 2004;  64 1164-1170
• 48 Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.  J Clin Oncol. 2004;  22 3549-3557
• 49 Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy.  Klin Padiatr. 2005;  217 147-152
• 50 Tiberghien P, Ferrand C, Lioure B, Milpied N, Angonin R, Deconinck E, Certoux J M, Robinet E, Saas P, Petracca B, Juttner C, Reynolds C W, Longo D L, Herve P, Cahn J Y. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.  Blood. 2001;  97 63-72
• 51 Troeger A, Meisel R, Moritz T, Dilloo D. Immunotherapy in allogeneic hematopoietic stem cell transplantation-not just a case for effector cells.  Bone Marrow Transplant. 2005;  35 (Suppl 1) S 59-S 64
• 52 Uherek C, Groner B, Wels W. Chimeric antigen receptors for the retargeting of cytotoxic effector cells.  J Hematother Stem Cell Res. 2001;  10 523-534
• 53 Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann H G, Wels W. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.  Blood. 2002;  100 1265-1273
• 54 Uhrberg M, Parham P, Wernet P. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes.  Immunogenetics. 2002;  54 221-229
• 55 Uhrberg M, Valiante N M, Shum B P, Shilling H G, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier L L, Parham P. Human diversity in killer cell inhibitory receptor genes.  Immunity. 1997;  7 753-763
• 56 Veys P, Amrolia P, Rao K. The role of haploidentical stem cell transplantation in the management of children with haematological disorders.  Br J Haematol. 2003;  123 193-206
• 57 Walter S, Herrgen L, Schoor O, Jung G, Wernet D, Buhring H J, Rammensee H G, Stevanovic S. Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres.  J Immunol. 2003;  171 4974-4978
• 58 Wels W, Biburger M, Muller T, Dalken B, Giesubel U, Tonn T, Uherek C. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors.  Cancer Immunol Immunother. 2004;  53 217-226
• 59 Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig W D, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95.  Blood. 2005;  105 948-958
• 60 Zhang H, Chua K S, Guimond M, Kapoor V, Brown M V, Fleisher T A, Long L M, Bernstein D, Hill B J, Douek D C, Berzofsky J A, Carter C S, Read E J, Helman L J, Mackall C L. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.  Nat Med. 2005;  11 1238-1243
• 61 Zimmermann S Y, Esser R, Rohrbach E, Klingebiel T, Koehl U. A novel four-colour flow cytometric assay to determine natural killer cell or T-cell-mediated cellular cytotoxicity against leukaemic cells in peripheral or bone marrow specimens containing greater than 20 % of normal cells.  J Immunol Methods. 2005;  296 63-76

1 The Meeting was supported by a Grant of the Kind Philipp Foundation, Mönchengladbach, Germany

2 Legally required testing provisions can be found, e. g., in the following documents: 1.) Annex I to Directive 2001/83/EC as amended by Directive 2003/63/EC 2.) European Note for guidance on the quality, preclinical and clinical aspects of gene transfer medicinal products (CPMP/BWP/3088/99) 3.) Points to consider document on the manufacture and quality control of human somatic cell therapy medicinal products published by the European Medicine Evaluation Agency, CPMP/BWP/41-450/98.